{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:28:19Z","timestamp":1790144899599,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T00:00:00Z","timestamp":1281830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T00:00:00Z","timestamp":1281830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/nchembio.421","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T14:25:27Z","timestamp":1281882327000},"page":"660-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery"],"prefix":"10.1038","volume":"6","author":[{"given":"Wolfgang","family":"Jahnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cotesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Marzinzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pell\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Geiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"G\u00f6tte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Bitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Hemmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryst\u00e8le","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Fraser","family":"Glickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Stout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,15]]},"reference":[{"key":"BFnchembio421_CR1","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9, 2643\u20132658 (2003).","journal-title":"Curr. Pharm. Des."},{"key":"BFnchembio421_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","volume":"257","author":"V Stresing","year":"2007","unstructured":"Stresing, V., Daubine, F., Benzaid, I., Monkkonen, H. & Clezardin, P. Bisphosphonates in cancer therapy. Cancer Lett. 257, 16\u201335 (2007).","journal-title":"Cancer Lett."},{"key":"BFnchembio421_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679\u2013691 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnchembio421_CR4","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1056\/NEJMoa043792","volume":"352","author":"JN Poynter","year":"2005","unstructured":"Poynter, J.N. et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352, 2184\u20132192 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnchembio421_CR5","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.1158\/0008-5472.CAN-08-2195","volume":"68","author":"PG Fournier","year":"2008","unstructured":"Fournier, P.G. et al. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res. 68, 8945\u20138953 (2008).","journal-title":"Cancer Res."},{"key":"BFnchembio421_CR6","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1021\/jm801003y","volume":"51","author":"D Simoni","year":"2008","unstructured":"Simoni, D. et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J. Med. Chem. 51, 6800\u20136807 (2008).","journal-title":"J. Med. Chem."},{"key":"BFnchembio421_CR7","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1021\/ja808285e","volume":"131","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. et al. Lipophilic bisphosphonates as dual farnesyl\/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J. Am. Chem. Soc. 131, 5153\u20135162 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnchembio421_CR8","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1021\/jm0702884","volume":"50","author":"MS Marma","year":"2007","unstructured":"Marma, M.S. et al. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J. Med. Chem. 50, 5967\u20135975 (2007).","journal-title":"J. Med. Chem."},{"key":"BFnchembio421_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrd2220","volume":"6","author":"PJ Hajduk","year":"2007","unstructured":"Hajduk, P.J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6, 211\u2013219 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnchembio421_CR10","doi-asserted-by":"crossref","unstructured":"Jahnke, W. & Erlanson, D.A. (eds.). Fragment-based Approaches in Drug Discovery (Wiley-VCH, 2006).","DOI":"10.1002\/3527608761"},{"key":"BFnchembio421_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nchem.217","volume":"1","author":"CW Murray","year":"2009","unstructured":"Murray, C.W. & Rees, D.C. The rise of fragment-based drug discovery. Nature Chemistry 1, 187\u2013192 (2009).","journal-title":"Nature Chemistry"},{"key":"BFnchembio421_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cmdc.200500059","volume":"1","author":"JM Rondeau","year":"2006","unstructured":"Rondeau, J.M. et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1, 267\u2013273 (2006).","journal-title":"ChemMedChem"},{"key":"BFnchembio421_CR13","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"KL Kavanagh","year":"2006","unstructured":"Kavanagh, K.L. et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. USA 103, 7829\u20137834 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnchembio421_CR14","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1002\/1521-3773(20020916)41:18<3420::AID-ANIE3420>3.0.CO;2-E","volume":"41","author":"W Jahnke","year":"2002","unstructured":"Jahnke, W. et al. NMR reporter screening for the detection of high-affinity ligands. Angew. Chem. Int. Edn Engl. 41, 3420\u20133423 (2002).","journal-title":"Angew. Chem. Int. Edn Engl."},{"key":"BFnchembio421_CR15","doi-asserted-by":"publisher","first-page":"8207","DOI":"10.1021\/ac062421q","volume":"79","author":"TP Roddy","year":"2007","unstructured":"Roddy, T.P. et al. Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal. Chem. 79, 8207\u20138213 (2007).","journal-title":"Anal. Chem."},{"key":"BFnchembio421_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/adt.2007.057","volume":"5","author":"JF Glickman","year":"2007","unstructured":"Glickman, J.F. & Schmid, A. Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay. Assay Drug Dev. Technol. 5, 205\u2013214 (2007).","journal-title":"Assay Drug Dev. Technol."},{"key":"BFnchembio421_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1087057108318757","volume":"13","author":"M Simonen","year":"2008","unstructured":"Simonen, M. et al. High-content assay to study protein prenylation. J. Biomol. Screen. 13, 456\u2013467 (2008).","journal-title":"J. Biomol. Screen."},{"key":"BFnchembio421_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1021\/jm7015733","volume":"51","author":"JE Dunford","year":"2008","unstructured":"Dunford, J.E. et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 51, 2187\u20132195 (2008).","journal-title":"J. Med. Chem."},{"key":"BFnchembio421_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1359-6446(05)03386-6","volume":"10","author":"C Abad-Zapatero","year":"2005","unstructured":"Abad-Zapatero, C. & Metz, J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 10, 464\u2013469 (2005).","journal-title":"Drug Discov. Today"},{"key":"BFnchembio421_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1021\/jm001020e","volume":"44","author":"F Wohnsland","year":"2001","unstructured":"Wohnsland, F. & Faller, B. High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes. J. Med. Chem. 44, 923\u2013930 (2001).","journal-title":"J. Med. Chem."},{"key":"BFnchembio421_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/17425255.2.6.823","volume":"2","author":"B Faller","year":"2006","unstructured":"Faller, B. et al. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis. Expert Opin. Drug Metab. Toxicol. 2, 823\u2013833 (2006).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnchembio421_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cmdc.201000016","volume":"5","author":"W Jahnke","year":"2010","unstructured":"Jahnke, W. & Henry, C. An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 5, 770\u2013776 (2010).","journal-title":"ChemMedChem"},{"key":"BFnchembio421_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00223-008-9123-8","volume":"82","author":"A Gozzetti","year":"2008","unstructured":"Gozzetti, A. et al. The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif. Tissue Int. 82, 258\u2013262 (2008).","journal-title":"Calcif. Tissue Int."},{"key":"BFnchembio421_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S8756-3282(02)00924-9","volume":"32","author":"A Montagnani","year":"2003","unstructured":"Montagnani, A. et al. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32, 15\u201319 (2003).","journal-title":"Bone"},{"key":"BFnchembio421_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/vhrm.1.1.29.58937","volume":"1","author":"J Davignon","year":"2005","unstructured":"Davignon, J. & Leiter, L.A. Ongoing clinical trials of the pleiotropic effects of statins. Vasc. Health Risk Manag. 1, 29\u201340 (2005).","journal-title":"Vasc. Health Risk Manag."},{"key":"BFnchembio421_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/1745509X.4.2.171","volume":"4","author":"A Rebollo","year":"2008","unstructured":"Rebollo, A., Pou, J. & Alegret, M. Cholesterol lowering and beyond: role of statins in Alzheimer's disease. Aging Health 4, 171\u2013180 (2008).","journal-title":"Aging Health"},{"key":"BFnchembio421_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1568005013343191","volume":"1","author":"R Docampo","year":"2001","unstructured":"Docampo, R. & Moreno, S.N. Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curr. Drug Targets Infect. Disord. 1, 51\u201361 (2001).","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"BFnchembio421_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nm1786","volume":"14","author":"I Varela","year":"2008","unstructured":"Varela, I. et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767\u2013772 (2008).","journal-title":"Nat. Med."},{"key":"BFnchembio421_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.chom.2007.06.009","volume":"2","author":"X Wang","year":"2007","unstructured":"Wang, X., Hinson, E.R. & Cresswell, P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2, 96\u2013105 (2007).","journal-title":"Cell Host Microbe"},{"key":"BFnchembio421_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0079-6565(02)00049-3","volume":"41","author":"BJ Stockman","year":"2002","unstructured":"Stockman, B.J. & Dalvit, C. NMR screening techniques in drug discovery and drug design. Progr. NMR Spectrosc. 41, 187\u2013231 (2002).","journal-title":"Progr. NMR Spectrosc."},{"key":"BFnchembio421_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"BFnchembio421_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1107\/S0021889893005588","volume":"26","author":"W Kabsch","year":"1993","unstructured":"Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 26, 795\u2013800 (1993).","journal-title":"J. Appl. Cryst."},{"key":"BFnchembio421_CR33","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1107\/S0907444904015215","volume":"60","author":"M Kroemer","year":"2004","unstructured":"Kroemer, M., Dreyer, M.K. & Wendt, K.U. APRV\u2014a program for automated data processing, refinement and visualization. Acta Crystallogr. D Biol. Crystallogr. 60, 1679\u20131682 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnchembio421_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1107\/S0907444998003254","volume":"D54","author":"AT Br\u00fcnger","year":"1998","unstructured":"Br\u00fcnger, A.T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. D54, 905\u2013921 (1998).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnchembio421_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1107\/S0108767390010224","volume":"A47","author":"TA Jones","year":"1991","unstructured":"Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A A47, 110\u2013119 (1991).","journal-title":"Acta Crystallogr. A"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nchembio.421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nchembio.421","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nchembio.421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:19:43Z","timestamp":1744352383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nchembio.421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,15]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnchembio421"],"URL":"https:\/\/doi.org\/10.1038\/nchembio.421","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4878956.4834054","asserted-by":"object"}]},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,15]]},"assertion":[{"value":"17 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are past or present full-time employees of Novartis AG and hold stock in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}